Displaying drugs 10451 - 10475 of 12589 in total
Netakimab
Netakimab is under investigation in clinical trial NCT03447704 (International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis).
Investigational
Matched Description: … Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis). ... trial NCT03447704 (International Multicenter Comparative Randomized Placebo-controlled Clinical Study of …
Mitiperstat
Mitiperstat is under investigation in clinical trial NCT05492877 (An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.).
Investigational
Matched Description: … (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.). ... Mitiperstat is under investigation in clinical trial NCT05492877 (An Efficacy and Safety Study of Mitiperstat …
Mequitazine
Mequitazine is a histamine H1 antagonist (antihistamine). It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory...
Experimental
Matched Description: … It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal ... It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay …
Fibrinolysin
Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a...
Investigational
Matched Description: … The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin ... ; the heavy chain has a molecular weight of approximately 57,000 Da. ... Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. …
PF-03187207
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Description: … of fluid in the eye, is believed to be one of the principal causes of glaucoma. ... The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount ... PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of …
Albinterferon Alfa-2B
Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human...
Investigational
Matched Description: … of cancers. ... Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. ... Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range …
PSN9301
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
Matched Description: … treatment of type 2 diabetes. ... PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the ... PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical …
Aetiocholanolone
The 5-beta-reduced isomer of androsterone. Etiocholanolone is a major metabolite of testosterone and androstenedione in many mammalian species including humans. It is excreted in the urine. [PubChem]
Experimental
Matched Description: … The 5-beta-reduced isomer of androsterone. ... Etiocholanolone is a major metabolite of testosterone and androstenedione in many mammalian species including …
Afelimomab
Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Investigational
Matched Description: … Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis. …
PF-06751979
PF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).
Investigational
Matched Description: … Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults). ... -06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of …
Hemoximer
Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.
Investigational
Matched Description: … Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering …
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Matched Description: … mutase (MUT) gene into the genome of patients with methylmalonic acidemia. ... LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA …
TST10088
TST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating proteins. These molecules efficiently kill cells by activating preprogrammed death pathways known as apoptosis. TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by...
Investigational
Matched Description: … TST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating ... Cleavage of the peptide switch activates the prodrug causing ribosomal inactivation and the death of …
IDM-4
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely...
Investigational
Matched Description: … IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of ... Trials of this drug have most likely been discontinued by the manufacturer. …
OSI-7836
OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside...
Investigational
Matched Description: … OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader ... The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. …
Horse chestnut
Horse chestnut is a flowering plant commonly referred to as Aesculus hippocastanum. Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions. These seeds are processed to remove the toxic component, resulting in purified horse chestnut seed extract...
Experimental
Matched Description: … the veins and reduces swelling and inflammation of the legs. ... Its therapeutic potential in the treatment of chronic venous insufficiency is being studied. ... horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of …
16-Bromoepiandrosterone
16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.
Investigational
Matched Description: … 16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. ... It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity …
Trebananib
Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.
Investigational
Matched Description: … Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian ... Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon …
Nivatrotamab
Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers).
Investigational
Matched Description: … Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of …
AVXS-301
AVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene. It is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Investigational
Matched Description: … It is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47077] ... AVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase …
BZL101
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Investigational
Matched Description: … BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of …
Bencyclane
A vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects. Its mechanism may involve block of calcium channels.
Experimental
Matched Description: … Its mechanism may involve block of calcium channels. ... A vasodilator agent found to be effective in a variety of peripheral circulation disorders. …
Lorecivivint
Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).
Investigational
Matched Description: … Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability ... , and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects …
JNJ-26489112
JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).
Investigational
Matched Description: … JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 …
Lulizumab pegol
Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Investigational
Matched Description: … the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome). ... Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate …
Displaying drugs 10451 - 10475 of 12589 in total